UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000007116
Receipt number R000008387
Scientific Title Effect of esomeprazole on symptom relief in patients with PPI-refractory GERD
Date of disclosure of the study information 2012/01/23
Last modified on 2015/02/23 13:03:04

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of esomeprazole on symptom relief in patients with PPI-refractory GERD

Acronym

Effect of esomeprazole on symptom relief in patients with PPI-refractory GERD

Scientific Title

Effect of esomeprazole on symptom relief in patients with PPI-refractory GERD

Scientific Title:Acronym

Effect of esomeprazole on symptom relief in patients with PPI-refractory GERD

Region

Japan


Condition

Condition

PPI-refractory GERD

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Although PPI is the first-line treatment for GERD, there is some cases with PPI failure. The aim of the study is to examine effect of esomeprazole, recently apperaed in Japanese market, on symptom relief in such cases.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Imrovement rate in GerdQ 4 weeks after esopmerazole treatment

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Patients with IC
2. Diagnosis as having reflux esophagitis by endoscopy during the past 12 months
3. 2-3 days and more in atleast one of Q1, Q2, Q5, Q6 of GerdQ

Key exclusion criteria

1. Esomeprazole allergy
2. Prescribing atazanavir sulfate
3. Esophageal stricture, IBS, IBD, Zollinger-Ellison syndrome, Malabsorption syndrome
4. Active gastric or duodenal ulcer by endoscopy
5. Sever Heart, kideny, liver diseases
6. Upper GI surgery
7. Pregnancy
8. PPI administration 14 days before trial
9. Co-treatment with H2RA, prokinetcis, other PPI etc.
10.Other drugs (diazepam, digoxin, etc.)

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yasuhiro Fujiwara

Organization

Osaka City University

Division name

Gastroentereology

Zip code


Address

1-4-3 Asahimachi, Abenoku, Osaka 545-8585

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Osaka City University

Division name

Gastroentereology

Zip code


Address


TEL


Homepage URL


Email

yasu@med.osaka-cu.ac.jp


Sponsor or person

Institute

Osaka City University, Department of Gastroenterology

Institute

Department

Personal name



Funding Source

Organization

Gastroentereology

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2012 Year 01 Month 23 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 11 Month 04 Day

Date of IRB


Anticipated trial start date

2012 Year 01 Month 01 Day

Last follow-up date

2014 Year 12 Month 31 Day

Date of closure to data entry

2014 Year 12 Month 31 Day

Date trial data considered complete


Date analysis concluded



Other

Other related information

Although PPI is the firstline treatment for GERD, there are some cases with PPI failure. The aim of the study is to examine effect of esomeprazole on symptoms relief in such cases by using specific symptom questionnaire and GERD-related QOL score (GerdQ).


Management information

Registered date

2012 Year 01 Month 23 Day

Last modified on

2015 Year 02 Month 23 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008387


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name